Jump to
Dr. Roukoz is an Associate Professor of Medicine in the Cardiovascular Medicine Division, Electrophysiology Section. His clinical interests include epicardial and endocardial ablation of complex arrhythmias (ventricular
tachycardia and atrial fibrillation) and implantation of EP medical devices. Dr. Roukoz is also part of the adult congenital program at the University of Minnesota, and this position permits him to be exposed to a wide range of exceptionally complex arrhythmias and ablation techniques.
Dr. Roukoz received his MD from Saint Joseph University in Beirut, Lebanon in 2004, and he completed an internship in internal medicine at the Hotel Dieu de France University Hospital, also in Beirut, in 2005. He did his internal medicine residency training at the Cleveland Clinic from 2005-2008, and completed two fellowships in Cardiology (2008-2011) and Electrophysiology (2011-2013) at the University of Minnesota. He has been on faculty at the University of Minnesota since 2013.
He received the Cleveland Clinical CLINSCHOP Award (Clinical Scholar Program) in 2006 and the University of Minnesota Department of Medicine Clinical Excellence Award in 2014.
MD, Saint Joseph's University
Sholevar DP, Tung S, Kuriachan V, Leong-Sit P, Roukoz H, Engel G, Kutalek SP, Akula D, Thompson AE, Christie MGT, Ostanniy M, Molin F; SPACE study investigators.Feasibility of Extravascular Pacing with a Novel Substernal Electrode Configuration: The Substernal Pacing Acute Clinical Evaluation (SPACE) Study: The Substernal Pacing Acute Clinical Evaluation Study. Heart Rhythm. 2017 Nov 29.[Epub ahead of print] [PMID: 29197657],
Roukoz H, Benditt DG. Atrial arrhythmias after lung transplantation. Trends Cardiovasc Med. 2017 Aug 1. pii: S1050-1738. [PMID 28797718],
Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, Okumura K, Serota H, Nordaby M, Guiver K, Biss B, Brouwer MA, Grimaldi M; RE-CIRCUIT Investigators. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med. 2017 Apr 27;376(17):1627-1636. [PMID: 28317415],
Chang IC, Agamawi YM, Austin E, Adkisson WO, Roukoz H, von Wald LN, Sakaguchi S, Benditt DG, Chen LY. Usefulness of Atrial Fibrillation as a Marker for Adverse Cardiovascular Outcomes in Both Primary and Secondary Prevention in Patients with Implantable Cardioverter-Defibrillators. American Journal of Cardiology. 2016;118(10): 1497-1502. [PMID 27649879],
Vakil K, Kazmirczak F, Sathnur N, Adabag S, Cantillon DJ, Kiehl EL, Koene R, Cogswell R, Anand I, Roukoz H. Implantable Cardioverter-Defibrillator Use in Patients With Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis. Journal of the American College of Cardiology Heart Failure. 2016;4(10):772-9. [PMID 27395347],
Clinical Excellence Award, University of Minnesota, Department of Medicine, 2014
Cleveland Clinic Clinical Scholar Program Award, 2006
Top Doctors: Rising Star (2016 - 2018)
Advanced device therapy, Atrial fibrillation ablation, Cardiac sarcoidosis, Congenital heart disease arrhythmia, Ventricular tachycardia ablation